SG11202011434SA - Methods for the treatment of bladder cancer - Google Patents
Methods for the treatment of bladder cancerInfo
- Publication number
- SG11202011434SA SG11202011434SA SG11202011434SA SG11202011434SA SG11202011434SA SG 11202011434S A SG11202011434S A SG 11202011434SA SG 11202011434S A SG11202011434S A SG 11202011434SA SG 11202011434S A SG11202011434S A SG 11202011434SA SG 11202011434S A SG11202011434S A SG 11202011434SA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- methods
- bladder cancer
- bladder
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679495P | 2018-06-01 | 2018-06-01 | |
| US201962826347P | 2019-03-29 | 2019-03-29 | |
| PCT/US2019/034933 WO2019232392A1 (en) | 2018-06-01 | 2019-05-31 | Methods for the treatment of bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011434SA true SG11202011434SA (en) | 2020-12-30 |
Family
ID=67138025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011434SA SG11202011434SA (en) | 2018-06-01 | 2019-05-31 | Methods for the treatment of bladder cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210205348A1 (zh) |
| EP (1) | EP3801561A1 (zh) |
| JP (1) | JP7335277B2 (zh) |
| KR (1) | KR20210015937A (zh) |
| CN (1) | CN112512531B (zh) |
| AU (1) | AU2019277679A1 (zh) |
| BR (1) | BR112020024605A2 (zh) |
| CA (1) | CA3101623A1 (zh) |
| MX (1) | MX2020012964A (zh) |
| SG (1) | SG11202011434SA (zh) |
| WO (1) | WO2019232392A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| CN117940124A (zh) | 2021-09-09 | 2024-04-26 | 卫材R&D管理有限公司 | Sting激动剂的生物标志物及其使用方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
| US7592326B2 (en) | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
| EP1729781B1 (en) | 2004-03-15 | 2012-10-24 | Karaolis, David K. R. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
| WO2009133560A1 (en) | 2008-04-29 | 2009-11-05 | Smart Assays | Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof |
| CN102199183B (zh) | 2010-03-26 | 2013-12-18 | 北京大学 | 环二鸟苷酸及其类似物和制备方法 |
| EP2931738B1 (en) | 2012-12-13 | 2019-02-06 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| WO2014179760A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
| MX354057B (es) | 2013-05-18 | 2018-02-09 | The Regents Of The Univ Of California Star | Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón". |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| US20160287623A1 (en) * | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
| WO2015074145A1 (en) | 2013-11-22 | 2015-05-28 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| US10450341B2 (en) | 2014-06-04 | 2019-10-22 | Glaxosmithkline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of STING |
| EP3233882B1 (en) | 2014-12-16 | 2019-10-30 | Kayla Therapeutics | Fluorinated cyclic dinucleotides for cytokine induction |
| EP3233089A4 (en) | 2014-12-17 | 2018-11-14 | Lipogen LLC | Method of treating cancer with cgamp or cgasmp |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| EP3334745B1 (en) | 2015-08-13 | 2024-05-15 | Merck Sharp & Dohme LLC | Cyclic di-nucleotide compounds as sting agonists |
| EP3368072A4 (en) | 2015-10-28 | 2019-07-03 | Aduro BioTech, Inc. | COMPOSITIONS AND METHOD FOR ACTIVATING SIGNALING DEPENDENT ON THE STIMULATOR OF THE INTERFERON GENE |
| CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| US10723756B2 (en) | 2016-01-11 | 2020-07-28 | Innate Tumor Immunity Inc. | Cyclic dinucleotides for treating conditions associated with STING activity such as cancer |
| KR20180132783A (ko) | 2016-04-07 | 2018-12-12 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 단백질 조절제로서 유용한 헤테로사이클릭 아미드 |
| JOP20170188A1 (ar) | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| WO2018140831A2 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| US20200055883A1 (en) | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
| WO2018198084A1 (en) | 2017-04-27 | 2018-11-01 | Lupin Limited | Cyclic di-nucleotide compounds with tricyclic nucleobases |
| AR113224A1 (es) * | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| JP7311514B2 (ja) | 2017-08-30 | 2023-07-19 | ベイジン シュエンイー ファーマサイエンシズ カンパニー， リミテッド | インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド |
| US11638716B2 (en) | 2017-08-31 | 2023-05-02 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| ES2945140T3 (es) | 2017-08-31 | 2023-06-28 | Bristol Myers Squibb Co | Dinucleótidos cíclicos como agentes anticancerosos |
| EP3676279B1 (en) | 2017-08-31 | 2021-12-01 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| US11667663B2 (en) | 2017-08-31 | 2023-06-06 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
-
2019
- 2019-05-31 CN CN201980050644.2A patent/CN112512531B/zh active Active
- 2019-05-31 WO PCT/US2019/034933 patent/WO2019232392A1/en unknown
- 2019-05-31 EP EP19734956.6A patent/EP3801561A1/en active Pending
- 2019-05-31 AU AU2019277679A patent/AU2019277679A1/en active Pending
- 2019-05-31 CA CA3101623A patent/CA3101623A1/en active Pending
- 2019-05-31 BR BR112020024605-0A patent/BR112020024605A2/pt unknown
- 2019-05-31 MX MX2020012964A patent/MX2020012964A/es unknown
- 2019-05-31 KR KR1020207037794A patent/KR20210015937A/ko active Search and Examination
- 2019-05-31 JP JP2020566898A patent/JP7335277B2/ja active Active
- 2019-05-31 US US17/058,817 patent/US20210205348A1/en active Pending
- 2019-05-31 SG SG11202011434SA patent/SG11202011434SA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3801561A1 (en) | 2021-04-14 |
| CA3101623A1 (en) | 2019-12-05 |
| US20210205348A1 (en) | 2021-07-08 |
| CN112512531B (zh) | 2024-04-09 |
| MX2020012964A (es) | 2021-02-16 |
| AU2019277679A1 (en) | 2020-12-24 |
| JP7335277B2 (ja) | 2023-08-29 |
| CN112512531A (zh) | 2021-03-16 |
| WO2019232392A1 (en) | 2019-12-05 |
| JP2021525758A (ja) | 2021-09-27 |
| KR20210015937A (ko) | 2021-02-10 |
| BR112020024605A2 (pt) | 2021-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3781564C0 (en) | PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | |
| HK1247129A1 (zh) | 治療癌症的聯合療法 | |
| IL267795A (en) | Combined treatment for cancer | |
| HK1251475A1 (zh) | 用於癌症治療的聯合療法 | |
| EP3610026A4 (en) | BLADDER CANCER TREATMENT METHODS | |
| ZA202005847B (en) | Cancer therapy | |
| SG11202011117VA (en) | Treatment of cancer | |
| ZA202206743B (en) | Therapy for the treatment of cancer | |
| SG11202010793UA (en) | Methods of treating cancer | |
| IL281845A (en) | Combined treatment for cancer | |
| IL284162A (en) | Integrated healing for cancer treatment | |
| IL266993A (en) | Combined therapy for cancer treatment | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| IL281600A (en) | Methods of treating cancer | |
| SG11202011434SA (en) | Methods for the treatment of bladder cancer | |
| IL277981A (en) | Cancer treatment methods | |
| IL282313A (en) | Abituzumab for the treatment of colorectal cancer | |
| GB201819920D0 (en) | Cancer treatment | |
| PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
| IL253642A0 (en) | Combined treatment for cancer | |
| EP3270898A4 (en) | Methods for the treatment of bladder cancer | |
| GB201820975D0 (en) | Methods of cancer treatment | |
| GB201820098D0 (en) | Methods of cancer treatment | |
| ZA202001435B (en) | Abx196 for use in the treatment of bladder cancer | |
| GB201811431D0 (en) | Cancer treatment |